Video

Scott Solomon from Brigham and Women's Hospital: Building Momentum to Help Heart Failure Patients

Author(s):

As new medications are introduced to the market there can be some hesitation by doctors to make the jump from more traditional treatment options. Moving beyond that has shown benefits for a patient's long term health.

As new medications are introduced to the market there can be some hesitation by doctors to make the jump from more traditional treatment options. Moving beyond that has shown benefits for a patient's long term health.

One such medication being studied in this effort is sacubitril/valsartan, also known as entresto. Scott David Solomon, MD, from Brigham & Women's Hospital and Harvard Medical School discussed the results of the Paradigm-HF trial which studied how the medication can help even "stable" heart failure patients. Solomon said the results of the study showed the benefit of this medication would work when compared to other patients including those ACE inhibitors or ARBs.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
© 2024 MJH Life Sciences

All rights reserved.